UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 39,772 Shares of IQVIA Holdings Inc. (NYSE:IQV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,226,083 shares of the medical research company’s stock after purchasing an additional 39,772 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in IQVIA were worth $290,545,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in IQV. Castle Hook Partners LP bought a new position in shares of IQVIA in the 3rd quarter valued at about $39,253,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of IQVIA by 34.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 100,603 shares of the medical research company’s stock worth $23,840,000 after purchasing an additional 25,778 shares during the last quarter. Providence Capital Advisors LLC raised its stake in shares of IQVIA by 1.5% during the 3rd quarter. Providence Capital Advisors LLC now owns 22,091 shares of the medical research company’s stock worth $5,235,000 after purchasing an additional 324 shares in the last quarter. CreativeOne Wealth LLC boosted its holdings in shares of IQVIA by 21.2% in the 3rd quarter. CreativeOne Wealth LLC now owns 3,167 shares of the medical research company’s stock valued at $750,000 after buying an additional 553 shares during the last quarter. Finally, Blueshift Asset Management LLC grew its stake in shares of IQVIA by 53.2% in the third quarter. Blueshift Asset Management LLC now owns 3,716 shares of the medical research company’s stock valued at $881,000 after buying an additional 1,290 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Friday, November 1st. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. BTIG Research dropped their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

IQVIA stock opened at $200.96 on Friday. The firm has a market cap of $36.47 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock’s fifty day moving average price is $218.67 and its two-hundred day moving average price is $226.20. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.